Editorial

289 Impaired Response to Immunotherapy in Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma?

Kudo, M. (Osaka-Sayama)

Original Papers

296 Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study

Qin, S. (Nanjing); Ren, Z. (Shanghai); Feng, Y.-H. (Tainan); Yau, T. (Hong Kong); Wang, B. (Jinan); Zhao, H. (Beijing); Bai, Y. (Harbin); Gu, S. (Changsha); Li, L. (Shanghai); Hernandez, S. (South San Francisco, CA); Xu, D.-Z. (Shanghai); Mulla, S. (Mississauga, ON); Wang, Y.; Shao, H. (Shanghai); Cheng, A.L. (Taipei)

309 Impact of Obesity and Heavy Alcohol Consumption on Hepatocellular Carcinoma Development after HCV Eradication with Antivirals

Minami, T.; Tateishi, R.; Fujiwara, N.; Nakagomi, R.; Nakatsuka, T.; Sato, M.; Uchino, K.; Enooku, K.; Nakagawa, H.; Fujinaga, H.; Izumiya, M.; Hanajiri, K.; Asaoka, Y.; Kondo, Y.; Tanaka, Y.; Otsuka, M.; Ohki, T. (Tokyo); Arai, M. (Toshiba); Tanaka, A.; Yasuda, K.; Miura, H.; Ogata, I. (Tokyo); Kamoshida, T. (Hitachi); Inoue, K. (Yokohama); Koike, Y.; Akamatsu, M.; Mitsui, H.; Fujie, H.; Ogura, K.; Yoshida, H.; Wada, T. (Tokyo); Kurai, K. (Utsunomiya); Maekawa, H.; Obi, S.; Teratani, T.; Masaki, N. (Tokyo); Nagashima, K. (Tachikawa); Ishikawa, T.; Kato, N.; Moriya, K.; Yotsuyanagi, H.; Koike, K. (Tokyo)

320 Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations

Zhu, X.-D.; Huang, C.; Shen, Y.-H.; Ji, Y.; Ge, N.-L.; Qu, X.-D.; Chen, L. (Shanghai); Shi, W.-K. (Zhengzhou); Li, M.-L.; Zhu, J.-J.; Tan, C.-J.; Tang, Z.-Y.; Zhou, J.; Fan, J.; Sun, H.-C. (Shanghai)

330 Disease Burden, Risk Factors, and Recent Trends of Liver Cancer: A Global Country-Level Analysis

Huang, J. (Hong Kong SAR); Lok, V. (Stockholm); Ngai, C.H.; Chu, C. (Hong Kong SAR); Patel, H.K. (New Orleans, LA); Thoguluva Chandraseka, V. (Scottsdale, AZ); Zhang, L. (Melbourne, VIC/Beijing); Chen, P.; Wang, S. (Shanghai); Lao, X.-Q. (Hong Kong SAR/Zhengzhou); Tse, L.A. (Hong Kong SAR); Xu, W. (Shanghai); Zheng, Z.-J. (Beijing); Wong, M.C.S. (Hong Kong SAR/Beijing)

346 Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma

Hsu, C.-L.; Ou, D.-L. (Taipei); Bai, L.-Y. (Taichung); Chen, C.-W.; Lin, L. (Taipei); Huang, S.-F. (Miaoli); Cheng, A.-L.; Jeng, Y.-M.; Hsu, C. (Taipei)

360 Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort

Finkelmeier, F. (Frankfurt); Scheiner, B. (Vienna); Leyh, C. (Essen); Best, J. (Magdeburg); Fr ?undt, T.W. (Hamburg); Czauderna, C. (Mainz/Lübeck); Beutel, A. (Ulm); Bettinger, D. (Freiburg); Wei β., J. (Würzburg); Meischl, T. (Vienna); Kütting, F.; Waldschmidt, D.-T. (Cologne); Radu, P. (Bern); Schulthei β, M. (Freiburg); Peiffer, K.-H. (Frankfurt); Ettrich, T.J. (Ulm); Weinmann, A. (Mainz); Wege, H. (Hamburg); Venerito, M. (Magdeburg); Dufour, J.-F. (Bern); Lange, C.M. (Essen); Pinter, M. (Vienna); Waidmann, O. (Frankfurt)

370 Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma

Tovoli, F. (Bologna); Dadduzio, V. (Padova); De Lorenzo, S. (Bologna); Rimassa, L. (Milan); Masi, G. (Pisa); Iavarone, M. (Milan); Marra, F. (Florence); Garajova, I. (Parma); Brizzi, M.P. (Orbassano); Daniele, B. (Napoli); Trevisani, F. (Bologna); Messina, C. (Trento); Di Clemente, F. (Montevarchi); Pini, S. (Rimini); Cabibbo, G. (Palermo); Granito, A. (Bologna); Rizzato, M.D. (Padova/Padua); Zagonel, V. (Padova); Brandi, G. (Bologna); Pressiani, T. (Milan); Federico, P. (Napoli); Vivaldi, C. (Pisa); Bergna, I. (Milan); Campani, C. (Florence); Piscaglia, F. (Bologna)

380 Immunological Microenvironment Predicts the Survival of the Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Antibody

Morita, M.; Nishida, N.; Sakai, K.; Aoki, T.; Chishina, H.; Takita, M.; Ida, H.; Hagiwara, S.; Minami, Y.; Ueshima, K.; Nishio, K. (Osaka); Kobayashi, Y.; Kakimi, K. (Tokyo); Kudo, M. (Osaka)

Letter to the Editor

394 Is the Strongest Level of Medical Evidence Always Required for Guidelines Recommendations?

Ravaioli, M.; Piscaglia, F. (Bologna); Cillo, U. (Padua); Brandi, G. (Bologna); Sessa, M. (Copenhagen); Germinario, G.; Golfieri, R.; Cappelli, A.; Morelli, M.C.; Siniscalchi, A.; D’Errico, A.; Cescon, M. (Bologna); Iannone, P. (Rome); Trevisani, F. (Bologna)

Society News

396 APPLE News

(doi: 10.1016/S1499-3872(21)00253-8)